Cellular HIV-1 Immune Responses in Natural Infection and After Genetic Immunization

References

• Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103–10.
   Google Scholar
• Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650–5.
   PubMed Web of Science ®Google Scholar
• Mackewicz CE, Blackbourn DJ, Levy JA. CD8 + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995; 92: 2308–12.
   Google Scholar
• Toso JF, Cen CH, Mohr JR, Piglia L, Oei C, Ferrari G, Greenberg ML, Weinhold KJ. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 1995; 172: 964–73.
   PubMedGoogle Scholar
• Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IPM, Eeftinck-Schattenkerk J-KM, Osterhaus ADME, Schuitemaker H, Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181: 1365–72.
   PubMed Web of Science ®Google Scholar
• Rinaldo C, Huang X-L, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, Gupta P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69: 5838–42.
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus ADME. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78: 1913–8.
   Google Scholar
• Rowland-Jones SL, Dong T, Dorrell L, Ogg G, Hansasuta P, Krausa P, Kimani J, Sabally S, Ariyoshi K, Oyugi J, MacDonald KS, Bwayo J, Whittle H, Plummer FA, McMichael AJ. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett 1999; 66: 9–14.
   PubMedGoogle Scholar
• Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, Wannebo C, Yannelli JR, Rosenberg SA, Lane HC. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1: 330–6.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216–23.
   Google Scholar
• Lieberman J, Skolnik PR, Parkerson GR, Fabry JA, Landry B, Bethel J, Kagan J. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 1997; 90: 2196–206.
   Google Scholar
• Brodie SJ, Lewinshon DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, Greenberg PD, Riddell SR. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5: 34–41.
   PubMed Web of Science ®Google Scholar
• Tan R, Xu X, Ogg GS, Hansasuta P, Dong T, Rostron T, Luzzi G, Conlon CP, Screaton GR, McMichael AJ, Rowland-Jones S. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999; 93: 1506–10.
   Google Scholar
• Wahren B, Brytting M. DNA increases the potency of vaccination against infectious diseases. Curr Opin Chem Biol 1997; 1: 183–9.
   PubMedGoogle Scholar
• Chattergoon M, Boyer J, Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J 1997; 11: 753–63.
   Google Scholar
• Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4156–60.
   PubMed Web of Science ®Google Scholar
• Fuller DH, Haynes JR. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994; 10: 1433–41.
   PubMed Web of Science ®Google Scholar
• Yasutomi Y, Robinson HL, Lu S, Mustafa F, Lekutis C, Arthos J, Mullins JI, Voss G, Manson K, Wyand M, Letvin NL. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 1996; 70: 678–81.
   Google Scholar
• Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson A-C, Sandström E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320–5.
   Google Scholar
• Calarota SA, Leandersson A-C, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandström E, Wahren B. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999; 163: 2330–8.
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92–100.
   Google Scholar
• Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol 1999; 90: 100–7.
   Google Scholar
• Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476–80.
   Google Scholar
• Kägi D, Seiler P, Pavlovic J, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. The roles of perforin- and Fas-de-pendent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995; 25: 3256–62.
   PubMedGoogle Scholar
• Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328: 345–8.
   PubMed Web of Science ®Google Scholar
• Plata F, Autran B, Martins LP, Wain-Hobson S, Raphaël M, Mayaud C, Denis M, Guillon J-M, Debré P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 1987; 328: 348–51.
   Google Scholar
• Walker BD, Plata F. Cytotoxic T lymphocytes against HIV. AIDS 1990; 4: 177–84.
   PubMed Web of Science ®Google Scholar
• Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, Plata F. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989; 142: 452–62.
   PubMed Web of Science ®Google Scholar
• Hadida F, Parrot A, Kieny M-P, Sadat-Sowti B, Mayaud C, Debre P, Autran B. Carboxyl-terminal and central regions of human immunodeficiency virus-1 nef recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest 1992; 89: 53–60.
   Google Scholar
• Jassoy C, Johnson RP, Navia BA, Worth J, Walker BD. Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J Immunol 1992; 149: 3113–9.
   Google Scholar
• Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksen-hendler E, Autran B, Wain-Hobson S. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994; 78: 373–87.
   Google Scholar
• Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997; 185: 293–303.
   PubMed Web of Science ®Google Scholar
• Ferbas J, Kaplan AH, Hausner MA, Hultin LE, Matud JL, Liu Z, Panicali DL, Nerng-Ho H, Detels R, Giorgi JV. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8 + lymphocyte activity. J Infect Dis 1995; 172: 329–39.
   Google Scholar
• McMichael AJ, Walker BD. Cytotoxic T lymphocyte epitopes: implications for HIV vaccines. AIDS 1994; 8 Suppl 1: S155–73.
   Google Scholar
• Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Ly TD, Goujard C, Guillet J-G, Gomard E. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection. AIDS 1995; 9: 421–6.
   PubMedGoogle Scholar
• Riviere Y, Robertson MN, Buseyne F. Cytotoxic T lymphocytes in human immunodeficiency virus infection: regulator genes. Curr Top Microbiol Immunol 1994; 189: 65–74.
   Google Scholar
• Littaua RA, Oldstone MBA, Takeda A, Ennis FA. A CD4 + cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6. J Virol 1992; 66: 608–11.
   PubMedGoogle Scholar
• Stanhope PE, Clements ML, Siliciano RF. Human CD4 + cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993; 168: 92–100.
   Google Scholar
• Koup RA, Pikora CA, Luzuriaga K, Brettler DB, Day ES, Mazzara GP, Sullivan JL. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantification of effector cell populations with p17 and p24 specificities. J Exp Med 1991; 174: 1593–600.
   Google Scholar
• Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Kieny M-P, Dreyfus F, Saimot A-G, Sereni D, Sicard D, Levy J-P, Gomard E. Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 1992; 6: 1249–58.
   PubMedGoogle Scholar
• Caramichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177: 249–56.
   PubMedGoogle Scholar
• Geretti AM, Dings ME, van Els CA, van Baalen CA, Wijn-holds FJ, Borleffs JC, Osterhaus AD. Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J Infect Dis 1996; 174: 34–45.
   Google Scholar
• Walker CM, Moody DJ, Stites DP, Levy JA. CD8 + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234: 1563–6.
   PubMed Web of Science ®Google Scholar
• Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8 + T cells. Immunol Today 1996; 17: 217–24.
   Google Scholar
• Barker E. CD8 + cell-derived anti-human immunodeficiency virus inhibitory factor. J Infect Dis 1999; 179 Suppl 3: S485–8.
   Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, and MIP- 1β as the major HIV-suppressive factors produced by CD8 + T cells. Science 1995; 270: 1811–5.
   Google Scholar
• Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature 1995; 378: 563.
   Google Scholar
• Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet 1994; 344: 1671–3.
   PubMedGoogle Scholar
• Autran B, Hadida F, Haas G. Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol 1996; 8: 546–53.
   PubMedGoogle Scholar
• Landay AL, Mackewicz CE, Levy JA. An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993; 69: 106–16.
   Google Scholar
• Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995; 154: 433–43.
   PubMedGoogle Scholar
• Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol 1997; 65: 277–346.
   PubMedGoogle Scholar
• van Baalen CA, Klein MR, Geretti AM, Keet RI, Miedema F, van Els CA, Osterhaus AD. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8 + T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS 1993; 7: 781–6.
   Google Scholar
• Lubaki MN, Egan MA, Siliciano RF, Weinhold KJ, Bollinger RC. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses 1994; 10: 1427–31.
   Google Scholar
• Spector DH, Wade E, Wright DA, Koval V, Clark C, Jaquish D, Spector SA. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 1990; 64: 2298–308.
   Google Scholar
• Lusso P, Di Marzo Veronese F, Ensoli B, Franchini G, Jemma C, DeRocco SE, Kalyanaraman VS, Gallo RC. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science 1990; 247: 848–52.
   PubMedGoogle Scholar
• Andäng M, Hinkula J, Hotchkiss G, Larsson S, Britton S, Wong-Staal F, Wahren B, Ährlund-Richter L. Dose-re-sponse resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model. Proc Natl Acad Sci USA 1999; 96: 12749–53.
   PubMed Web of Science ®Google Scholar
• Altman J, Moss PAH, Goulder P, Barouch D, McHeyzer-Williams M, Bell JI, McMichael AJ, Davis MM. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science 1996; 274: 94–6.
   Google Scholar
• Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AVS, McMichael AJ. Rapid effector function in CD8 + memory T cell. J Exp Med 1997; 186: 859–65.
   PubMed Web of Science ®Google Scholar
• Murali-Krishna K, Altman JD, Suresh M, Sourdive DJD, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. Immunity 1998; 8: 177–87.
   PubMed Web of Science ®Google Scholar
• Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998; 212: 89–98.
   Google Scholar
• Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI, Steinman RM, Nixon D, Bhardwaj N. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999; 13: 767–77.
   Google Scholar
• Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995; 7: 448–55.
   PubMed Web of Science ®Google Scholar
• Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 17: 21–4.
   PubMedGoogle Scholar
• Heeney JL, Beverley P, McMichael A, Shearer G, Strominger J, Wahren B, Weber J, Gotch F. Immune correlates of protection from HIV and AIDS – more answers but yet more questions. Immunol Today 1999; 20: 247–51.
   PubMedGoogle Scholar
• Bernard NF, Yannakis CM, Lee JS, Tsoukas CM. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 1999; 179: 538–47.
   PubMedGoogle Scholar
• Goh WC, Markee J, Akridge RE, Meldorf M, Musey L, Karchmer T, Krone M, Collier A, Corey L, Emerman M, McElrath MJ. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179: 548–57.
   Google Scholar
• Franco A, Ferrari C, Sette A, Chisari FV. Viral mutations, TCR antagonism and escape from the immune response. Curr Opin Immunol 1995; 7: 524–31.
   PubMedGoogle Scholar
• Matsui M, Warburton RJ, Cogswell PC, Baldwin AS, Frelinger JA. Effects of HIV-1 Tat on expression of HLA class I molecules. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 233–40.
   PubMedGoogle Scholar
• Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard J-M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2: 338–42.
   PubMed Web of Science ®Google Scholar
• Koup RA. Virus escape from CTL recognition. J Exp Med 1994; 180: 779–82.
   PubMedGoogle Scholar
• McMichael A. T cell responses and viral escape. Cell 1998; 93: 673–6.
   PubMed Web of Science ®Google Scholar
• Couillin I, Culmann-Penciolelli B, Gomard E, Choppin J, Levy J-P, Guillet J-G, Saragosti S. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 Nef protein. J Exp Med 1994; 180: 1129–34.
   PubMed Web of Science ®Google Scholar
• Klenerman P, Rowland-Jones S, McAdam S, Edwards J, Daenke S, Lalloo D, Köppe B, Rosenberg W, Boyd D, Edwards A, Giangrande P, Phillips RE, McMichael AJ. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994; 369: 403–10.
   PubMed Web of Science ®Google Scholar
• Meier U-C, Klenerman P, Griffin P, James W, Köppe B, Larder B, McMichael A, Phillips R. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 1995; 270: 1360–2.
   PubMed Web of Science ®Google Scholar
• Klein MR, van der Burg SH, Pontesilli O, Miedema F. Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? Immunol Today 1998; 19: 317–24.
   PubMedGoogle Scholar
• Wahren B, Morfeldt-Månsson L, Biberfeld G, Moberg L, Ljungman P, Nordlund S, Bredberg-Rådén U, Werner A, Löwer J, Kurth R. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986; 315: 393–4.
   PubMedGoogle Scholar
• Shearer GM, Clerici M. Early T-helper cell defects in HIV infection. AIDS 1991; 5: 245–53.
   PubMed Web of Science ®Google Scholar
• Wahren B, Morfeldt-Mansson L, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P, Werner A, Kurth R, Gallo R, Bolognesi D. Characteristics of the specific cell-mediated immune responses in human immunodeficiency virus infection. J Virol 1987; 61: 2017–23.
   PubMedGoogle Scholar
• Pontesilli O, Carlesimo M, Varani AR, Ferrara R, Guerra EC, Bernardi ML, Ricci G, Mazzone AM, D’Offizi G, Aiuti F. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol 1995; 100: 419–24.
   Google Scholar
• Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses 1998; 14: S143–7.
   PubMed Web of Science ®Google Scholar
• Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke DS, and the Military Medical Consortium for Applied Retroviral Research. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324: 1677–84.
   Google Scholar
• Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 26974.
   Google Scholar
• Wahren B, Bratt G, Persson C, Levén B, Hinkula J, Gilljam G, Nordlund S, Eriksson L, Volvovitz F, Broliden PA, Sandström E. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994; 7: 220–9.
   Google Scholar
• Leandersson A-C, Bratt G, Hinkula J, Gilljam G, Cochaux P, Samson M, Sandström E, Wahren B. Induction of specific T-cell responses in HIV infection. AIDS 1998; 12: 157–66.
   PubMedGoogle Scholar
• Sandström E, Wahren B, Nordic VAC-04 Study Group. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Lancet 1999; 353: 1735–42.
   PubMed Web of Science ®Google Scholar
• Ratto-Kim S, Sitz KV, Garner RP, Kim JH, Davis C, Aronson N, Ruiz N, Tencer K, Redfield RR, Birx DL. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J Infect Dis 1999; 179: 337–44.
   PubMed Web of Science ®Google Scholar
• Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89–97.
   PubMedGoogle Scholar
• Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gen-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478–82.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–9.
   Google Scholar
• Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997; 3: 526–32.
   Google Scholar
• Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152–4.
   Google Scholar
• Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglubulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996; 70: 6119–25.
   Google Scholar
• Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158: 2278–84.
   PubMed Web of Science ®Google Scholar
• Asakura Y, Hinkula J, Leandersson A-C, Fukushima J, Okuda K, Wahren B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 1997; 46: 326–30.
   Google Scholar
• Corr M, Tighe H. Plasmid DNA vaccination: mechanism of antigen presentation. Springer Semin Immunopathol 1997; 19: 139–45.
   PubMed Web of Science ®Google Scholar
• Robinson HL. Nucleic acid vaccines: an overview. Vaccine 1997; 15: 785–7.
   PubMedGoogle Scholar
• Fu T-M, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3: 362–71.
   PubMed Web of Science ®Google Scholar
• Liu MA, Fu T-M, Donnelly JJ, Caulfield MJ, Ulmer JB. DNA vaccines: mechanisms for generation of immune responses. Adv Exp Med Biol 1998; 452: 187–91.
   PubMedGoogle Scholar
• Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999; 163: 4721–7.
   PubMed Web of Science ®Google Scholar
• Wahren B, Brytting M, Engström G, Hinkula J, Levi M, Ljungdahl-Ståhle E, Ohlsson S, Rudén U, Schwartz S. Immune responses to the HIV rev regulatory gene. Antibiot Chemother 1996; 48: 105–12.
   Google Scholar
• Korber BTM, Haynes BF, Koup R, Brander C, Moore JP, Walker BD, editors. HIV Molecular Immunology Database 1998. Theoretical Biology and Biophysics Group. Los Alamos, NM: Los Alamos National Laboratory.
   Google Scholar
• Huang L, Bosh I, Hofmann W, Sodroski J, Pardee AB. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophagetropic and T-lymphotropic HIV-1 strains. J Virol 1998; 72: 8952–60.
   Google Scholar
• Kalland K-H, Szilvay AM, Brokstad KA, Saetrevik W, Haukenes G. The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasms and nuclear compartments. Mol Cell Biol 1994; 14: 7436–44.
   PubMedGoogle Scholar
• Miller RH, Sarver N. HIV accessory proteins as therapeutic targets. Nat Med 1997; 3: 389–94.
   PubMedGoogle Scholar
• Braun R, Babiuk LA, van Drunen Littel-van den Hurk S. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 1998; 79: 2965–70.
   Google Scholar
• Kjerrström A, Wahren B. Expression of HIV regulatory DNA vaccine constructs. Biogenic Amines 1999; 15: 93–112.
   Google Scholar
• Hinkula J, Lundholm P, Wahren B. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 1997; 15: 874–8.
   Google Scholar
• McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996; 93: 11414–20.
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Popovic M, Gartner S, Markham P, Gallo RC, Reitz MS. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol 1990; 64: 3391–8.
   PubMedGoogle Scholar
• Shugars D, Smith MS, Glueck DH, Nantermet PV, Seillier-Moiseiwitsch F, Swanstrom R. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol 1993; 67: 4639–50.
   Google Scholar
• Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391: 397401.
   Google Scholar
• Kelleher AD, Roggensack M, Jaramillo AB, Smith DE, Walker A, Gow I, McMurchie M, Harris J, Patou G, Cooper DA, and the Community HIV Research Network Investigators. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 1998; 12: 175–82.
   Google Scholar
• Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112–6.
   Google Scholar
• Li TS, Tubiana R, Katlama C, Calvez V, Ait-Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682–6.
   Google Scholar
• Ogg GS, Jin X, Bonhoeffer S, Rod Dunbar P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA. Science 1998; 279: 2103–6.
   Google Scholar
• Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, Nixon DF. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73: 797–800.
   Google Scholar
• Dalod M, Harzic M, Pellegrin I, Dumon B, Hoen B, Sereni D, Deschemin J-C, Levy J-P, Venet A, Gomard E. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998; 178: 61–9.
   Google Scholar
• Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Ji X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179: 525–37.
   Google Scholar
• Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 121–31.
   PubMedGoogle Scholar
• Kaufmann GR, Zaunders J, Cooper DA. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect 1999; 75: 218–24.
   Google Scholar
• Pontesilli O, Kerkhof-Garde S, Pakker NG, Notermans DW, Roos MT, Klein MR, Danner SA, Miedema F. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 1999; 66: 213–7.
   PubMedGoogle Scholar
• Pontesilli O, Kerkhof-Garde S, Notermans DW, Foudraine NA, Roos MT, Klein MR, Danner SA, Lange JM, Miedema F. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180: 76–86.
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–9.
   PubMed Web of Science ®Google Scholar
• Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17: 19–25.
   PubMed Web of Science ®Google Scholar
• Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen M-D, Silverman GJ, Lotz M, Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352–4.
   Google Scholar
• Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849–54.
   PubMed Web of Science ®Google Scholar
• Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 1995; 772: 30–9.
   PubMed Web of Science ®Google Scholar
• Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, Hobart P, Lew D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999; 10: 759–68.
   PubMed Web of Science ®Google Scholar
• Ertl HCJ, Xiang Z. Novel vaccine approaches. J Immunol 1996; 156: 3579–82.
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 2000; 181: 406.
   Google Scholar
• Isaguliants MG, Ivanova OV, Iakimtchouk KS, Garaev MM, Hinkula J, Wahren B. Multiple injections of plasmid encoding HIV-1 reverse transcriptase induce antibodies against double-stranded DNA. The 4th European Conference on Experimental AIDS Research (ECEAR ’99). 18–21 June 1999. [Abstract no. P71].
   Google Scholar
• Livingstone WJ, Moore M, Innes D, Bell JE, Simmonds P, and the Edinburgh Heterosexual Transmission Study Group. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Lancet 1996; 348: 649–54.
   Google Scholar
• Joly P, Guillon J-M, Mayaud C, Plata F, Theodorou I, Denis M, Debre P, Autran B. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol 1989; 143: 2193–201.
   PubMedGoogle Scholar
• Sadat-Sowti B, Debre P, Idziorek T, Guillon J-M, Hadida F, Okzenhendler E, Katlama C, Mayaud C, Autran B. A lectinbinding soluble factor released by CD8 + CD57 + lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol 1991; 21: 737–41.
   PubMed Web of Science ®Google Scholar
• Gotch F. Cross-clade T cell recognition of HIV-1. Curr Opin Immunol 1998; 10: 388–92.
   PubMedGoogle Scholar
• Calarota SA. Modulation of HIV immune responses in natural infection and after genetic immunization [dissertation]. Karolinska Institute, Stockholm, Sweden. 1999. ISBN 91628–3678–1.
   Google Scholar
• El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8 + cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993; 168: 306–13.
   PubMedGoogle Scholar
• Perales M-A, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 27–35.
   PubMedGoogle Scholar
• Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G, and the AIDS Vaccine Evaluation Group. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998; 177: 301–9.
   Google Scholar
• Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, Riviere Y. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996; 174: 734–8.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler J-L, Duliege A-M, Tartaglia J, Cox WI, McNamara J, Hwang K-L, Bradney A, Montefiori D, Weinhold KJ for the NIAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12: 2407–15.
   Google Scholar
• Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh R-H, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler J-L, Tartaglia J, Duliege A-M, Sinangil F, Paoletti E, and the NIAID AIDS Vaccine Evaluation Group. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998; 177: 1230–46.
   Google Scholar
• Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler J-L, Duliege A-M, Tartaglia J, and the NIAID AIDS Vaccine Evaluation Group. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8 + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180: 290–8.
   Google Scholar
• Shearer GM, Bernstein DC, Tung KS, Via CS, Redfield R, Salahuddin SZ, Gallo RC. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986; 137: 2514–21.
   Google Scholar
• Clerici M, Shearer GM. A Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107–11.
   PubMedGoogle Scholar
• Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landy AL, Shearer GM. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 271: 42–6.
   Google Scholar
• Mathiesen T, Broliden P-A, Rosen J, Wahren B. Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides. Immunology 1989; 67: 453–9.
   PubMedGoogle Scholar
• Wahren B, Rosen J, Sandström E, Mathiesen T, Modrow S, Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immune Defic Syndr 1989; 2: 448–56.
   Google Scholar
• Nixon DF, Broliden K, Ogg G, Broliden P-A. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992; 76: 515–34.
   Google Scholar
• Siliciano RF. CD4 + T cell epitopes in HIV-1 proteins. Chem Immunol 1993; 56: 127–49.
   PubMedGoogle Scholar
• Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh R-H, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE, for the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. J Infect Dis 1996; 173: 330–9.
   Google Scholar
• Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O’Brien FS, Eibl M, Dorner F, Koff W, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168: 1387–95.
   Google Scholar
• Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE and the NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med 1996; 125: 270–9.
   Google Scholar
• Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh R-H, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB, for the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1999; 15: 115–32.
   Google Scholar
• Pialoux G, Excler J-L, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman J-C, Matthews TJ, Meignier B, Kieny M-P, Gonnet P, Diaz I, Meric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, The AGIS Group, and L’Agence Nationale de Recherche sur le SIDA. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995; 11: 373–81.
   PubMed Web of Science ®Google Scholar
• Graham BS, Belshe RB, Clements ML, Dolin ML, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ, Schwartz DH, Agosti JM, Fernie BF, Stablein DM, Montefiori DC, Lambert JS, Hu S-L, Esterlitz JR, Lawrence DN, Koff WC, and the AIDS Vaccine Clinical Trials Network. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992; 166: 244–52.
   Google Scholar
• Ljunggren K, Böttiger B, Biberfeld G, Karlson A, Fenyö EM, Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987; 139: 2263–7.
   Google Scholar
• Tyler DS, Lyerly HK, Weinhold KJ. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses 1989; 5: 557–63.
   PubMedGoogle Scholar
• Koup RA, Pikora CA, Mazzara G, Panicali D, Sullivan JL. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 1991; 4: 215–23.
   Google Scholar
• Tyler DS, Stanley SD, Nastala CA, Austin AA, Bartlett JA, Stine KC, Lyerly HK, Bolognesi DP, Weinhold KJ. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144: 3375–84.
   Google Scholar
• Broliden K, Hinkula J, Bratt G, Persson C, Otero A, Ekström A, Sandström E, Broliden P-A, Wahren B. Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160. Clin Diagn Virol 1996; 6: 115–26.
   Google Scholar
• Brander C, Walker BD. Systematic identification of optimal HIV-1 CTL epitopes. In: Korber BTM, Haynes BF, Koup R, Brander C, Moore JP, Walker BD, editors. HIV Molecular Immunology Database 1998. Theoretical Biology and Biophysics Group. Los Alamos, NM: Los Alamos National Laboratory.
   Google Scholar
• Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, Walker BD, Johnson RP. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996; 70: 5799–806.
   PubMed Web of Science ®Google Scholar
• Jassoy C, Harrer T, Rosenthal T, Navia BA, Worth J, Johnson RP, Walker BD. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J Virol 1993; 67: 2844–52.
   Google Scholar
• Price P, Johnson RP, Scadden DT, Jassoy C, Rosenthal T, Kalams S, Walker BD. Cytotoxic CD8 + T lymphocytes reactive with human immunodeficiency virus-1 produce granulocyte/macrophage colony-stimulating factor and variable amounts of interleukins 2, 3, and 4 following stimulation with the cognate epitope. Clin Immunol Immunopathol 1995; 74: 100–6.
   Google Scholar
• Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994; 15: 262–8.
   PubMedGoogle Scholar
• Harrer T, Jassoy C, Harrer E, Johnson RP, Walker BD. Induction of HIV-1 replication in a chronically infected T-cell line by cytotoxic T lymphocytes. J Acquir Immune Defic Syndr 1993; 6: 865–71.
   Google Scholar